Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Type 2 Diabetes | Unmet Need | Oral Medications | US/EU | 2020

Login to access report north_east
Contact sales account_box

The type 2 diabetes (T2D) drug market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging therapies will be predominantly later-to-market entrants of existing drug classes or combination treatments. Owing to the increased risk of cardiovascular (CV) and kidney disease associated with T2D, a high unmet need exists for affordable drugs that can safely and effectively manage this disease in the long term. The sodium-glucose co-transporter-2 (SGLT-2) inhibitors, such as AstraZeneca’s Farxiga / Forxiga, and glucagon-like peptide-1 (GLP-1) receptor agonists, such as Novo Nordisk’s Ozempic, are offering hope for greater CV and renal benefits. However, the physical and financial impacts of T2D continue to increase, highlighting the need for more-effective and more-affordable drug treatments.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for type 2 diabetes?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for type 2 diabetes?
  • What are the prevailing areas of unmet need and opportunity in type 2 diabetes?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European endocrinologists for a hypothetical new type 2 diabetes drug?

PRODUCT DESCRIPTION

Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 32 European endocrinologists fielded in March 2020

Key companies: AstraZeneca, Eli Lilly, Janssen, Merck, Novo Nordisk

Key drugs: Farxiga / Forxiga, Invokana, Januvia, Jardiance, Rybelsus, Trulicity, Victoza

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Chronic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Back Pain (US)
Approximately 30 million people in the United States have chronic back pain (CBP). Treatment of CBP poses a challenge to physicians owing to the heterogeneity of pain pathophysiology and the…
north_east
Report
Post-Traumatic Stress Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Post-Traumatic Stress Disorder (US)
Multiple guidelines recommend treating post-traumatic stress disorder (PTSD) first with psychotherapy. However, such approaches do not suffice for many patients, necessitating the use of…
north_east
Report
Type 1 Diabetes – Current Treatment – Treatment Algorithms: Claims Data Analysis – Type 1 Diabetes (US)
Intensive insulin regimens have proven effective in delaying the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulin remains the…
north_east
Report
Postpartum Depression – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postpartum Depression (US)
Postpartum depression (PPD) refers to depression experienced by women after childbirth. The PPD drug market consists of very limited treatment options specifically approved for PPD, so drugs used…
north_east
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east